Astellas’ VYLOY™ Approved by U.S. FDA
VYLOY is a groundbreaking treatment that targets CLDN18.2, now approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancers, particularly for those whose tumors are CLDN18.2 positive.
FDA Approval and Indications
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) alongside chemotherapy regimens for the first-line treatment of adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. This is a significant milestone as VYLOY becomes the first-targeted therapy of its kind in the U.S.
Clinical Trial Insights
The approval of VYLOY is based on data from pivotal clinical trials, including SPOTLIGHT and GLOW, which found that around 38% of patients screened had claudin (CLDN) 18.2 positive tumors. CLDN18.2 positivity is defined as moderate to strong immunohistochemical staining in at least 75% of tumor cells.
Partnership with Roche
For effective patient identification, Astellas worked in collaboration with Roche to develop the VENTANA CLDN18 (43-14A) RxDx Assay, an FDA-approved test essential for determining eligibility for VYLOY treatment.
Expert Opinions on VYLOY Approval
Dr. Moitreyee Chatterjee-Kishore from Astellas emphasized the importance of this breakthrough, stating that this treatment offers hope to patients battling serious diseases like gastric cancers, which are frequently diagnosed at later stages. The company’s commitment to scientific progress in the field of oncology is underscored in this achievement.
Oncologist Perspective
Dr. Samuel J. Klempner, a medical oncologist and professor, highlighted the ongoing unmet needs among patients with advanced gastric and GEJ cancers despite recent treatment advancements. He noted that the emergence of VYLOY offers a new therapeutic option based on the robust data from the Phase 3 clinical trials.
Clinical Evidence Supporting VYLOY Use
Both the SPOTLIGHT and GLOW trials successfully met their primary endpoint, demonstrating significant improvements in progression-free survival (PFS) and overall survival (OS) among those treated with VYLOY in conjunction with standard chemotherapy compared to those receiving a placebo. Treatment-emergent adverse events commonly noted included nausea and vomiting, presenting a clear profile of the treatment regimen.
Ongoing Tests and Accessibility
The VENTANA CLDN18 RxDx Assay is widely available in multiple reference laboratories across the U.S., with plans for broader access in the future.
Global Market Approval
With the recent FDA approval, VYLOY is also recognized in several international markets including Japan, the United Kingdom, South Korea, and the European Union. These approvals pave the way for Astellas to continue advocating for widespread access to innovative cancer therapies across various regions.
Future Developments in Cancer Research
Astellas remains dedicated to research in the oncology sector with ongoing trials looking into other potential treatments, reflective of their commitment to addressing high unmet medical needs in cancer care.
Frequently Asked Questions
What is VYLOY used for?
VYLOY is approved for the first-line treatment of adults with advanced gastric and gastroesophageal junction cancers whose tumors are CLDN18.2 positive.
How does VYLOY work?
VYLOY works by targeting CLDN18.2, leading to the destruction of malignant cells through antibody-dependent cellular cytotoxicity.
What are the common side effects of VYLOY?
Common side effects include nausea, vomiting, and decreased appetite, which were reported during clinical trials.
Is VYLOY available in other countries?
Yes, VYLOY has received approval in multiple markets worldwide, including Japan and Europe.
What is the role of the VENTANA CLDN18 test?
The VENTANA CLDN18 test is used to determine if a patient’s tumor is suitable for treatment with VYLOY, facilitating targeted therapy for eligible patients.
